Cold and flu season boosts demand for Strepsils at Reckitt Benckiser

Consumer products giant Reckitt Benckiser reported decent growth in the first quarter with its Health division performing strongly as a more favourable cold and flu season increased the demand for Strepsils, Mucinex and certain Nurofen products.

Consumer products giant Reckitt Benckiser reported decent growth in the first quarter with its Health division performing strongly as a more favourable cold and flu season increased the demand for Strepsils, Mucinex and certain Nurofen products.

Net revenue tolled £2,517m in the first three months of 2013, up 7.0% at constant currency and 7.0% higher on a like-for-like basis. Excluding Reckitt Benckiser Pharmaceuticals (RBP), growth was 6.0%.

The firm said that it is well-placed to achieved its full-year target for revenue growth of 5-6% at constant exchange (excluding RBP).

Health, which accounts for 27% of revenues, saw sales grow 30% (up 13% on a LFL basis) to £597m as all of its 'powerbrands' registered growth due to strong performances from flu-related brands.

"This was due to higher incidences of cold and flu in the US supported by increased TV and digital BEI initiatives as we leveraged increased cold & flu search volumes."

The Durex brand was also performing well, helped from greater exposure in China and the roll-out of a new product in a number of markets.

The biggest division, Hygiene (46% of revenue), registered 7.0% growth (LFL up 9.0%) driven by strong growth in the Dettol and Lysol brands across both the emerging markets, and Europe and North America.

The Home division (22% of revenue) reported sales of £488m, unchanged on last year on a reported basis (LFL up 2.0%) was a difficult consumer environment weighed on the performance.

RBP saw strong growth of 19%, helped by underlying growth in prescriptions in the US. "As signalled with our 2012 full year numbers, the Q1 2013 reported growth was increased by the sell-in to drug wholesalers of new 4mg and 12mg film dosages, and the tail of the high Medicaid accruals in Q1 2012."

Recommended

Share tips of the week – 30 September
Share tips

Share tips of the week – 30 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
30 Sep 2022
The best British tech stocks from a thriving sector
Share tips

The best British tech stocks from a thriving sector

Move over, Silicon Valley. Over the past two decades the UK has become one of the main global hubs for tech start-ups. Matthew Partridge explains why,…
29 Sep 2022
These 3 top value stocks offer
Share tips

These 3 top value stocks offer

Professional investor Adam Rackley of Cape Wrath Capital highlights three overlooked value stocks to buy.
29 Sep 2022
Three top-notch Asian stocks to buy
Share tips

Three top-notch Asian stocks to buy

Professional investors Adrian Lim and Pruksa Iamthongthong, managers of the Asia Dragon Trust, pick three of their favourite Asian stocks to buy now.
23 Sep 2022

Most Popular

Why everyone is over-reacting to the mini-Budget
Budget

Why everyone is over-reacting to the mini-Budget

Most analyses of the chancellor’s mini-Budget speech have failed to grasp its purpose and significance, says Max King
29 Sep 2022
How the end of cheap money could spark a house price crash
House prices

How the end of cheap money could spark a house price crash

Rock bottom interest rates drove property prices to unaffordable levels. But with rates set to climb and cheap money off the table, we could see house…
28 Sep 2022
What to do as the age of cheap money and overpriced equities ends
Investment strategy

What to do as the age of cheap money and overpriced equities ends

The age of cheap money, overpriced equities and negative interest rates is over. The great bond bull market is over. All this means you will be losin…
29 Sep 2022